15 July 2014 | Regulatory | By BioSpectrum Bureau
QLF facility is a combination of both pre-extraction plant (TCM) and formulation plant
Singapore: China-based Tianyin Pharmaceutical is looking ahead to get its Qionglai Facility (QLF) GMP certified post insepction by China Food and Drug Administration (CFDA) expected to begin in early August.
QLF facility is a combination of both pre-extraction plant (TCM) and formulation plant. The pre-extraction facility is designed to process and purify raw materials for traditional Chinese medicine (TCM) using ethanol or distilled water precipitation, filtration, centrifugation, concentration and purification, which will be further processed for the production of modernized TCM products at the formulation facility where the final biopharmaceutical, TCM and generic products in the forms of oral liquid, granules, tablets, and capsules are produced.
QLF, after the completion of its construction followed by the equipment installation, has conducted a series of procedures and tests that prepare the facility for GMP certification.